



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/643,579	08/22/2000	Richard Martin Broglie	BB1334 USNA CNTI	3114

7590 04/11/2002

CARGILL INCORPORATED
P.O. BOX 5624 MS 24
MINNEAPOLIS, MN 55440-5624

EXAMINER

KALLIS, RUSSELL

ART UNIT	PAPER NUMBER
1638	

DATE MAILED: 04/11/2002

8

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application N .	Applicant(s)
	09/643,579	BROGLIE ET AL.
	Examiner	Art Unit
	Russell Kallis	1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____ .

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-36 is/are pending in the application.

4a) Of the above claim(s) ____ is/are withdrawn from consideration.

5) Claim(s) ____ is/are allowed.

6) Claim(s) ____ is/are rejected.

7) Claim(s) ____ is/are objected to.

8) Claim(s) 1-36 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. ____ .

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ .

4) Interview Summary (PTO-413) Paper No(s) ____ .

5) Notice of Informal Patent Application (PTO-152)

6) Other: ____ .

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, 23-25, 29, 36 are drawn to a *Brassica canola* plant transformed with a full length mutant microsomal $\Delta 12$ fatty acid desaturase gene from *Brassica napus*, having 69-90% linoleic acid of total fatty acid in the seeds, and the method of transformation, classified in class 800, subclass 278 for example.
- II. Claims 10-17, 26-28, 30 are drawn to a *Brassica canola* plant transformed with a full length $\Delta 15$ mutant microsomal fatty acid desaturase gene from *Brassica napus*, having 1-10% linolenic acid of total fatty acid in the seeds, and the method of transformation, classified in class 800, subclass 298 for example.
- III. Claims 18-22 are drawn to a *Brassica canola* plant transformed with a full length mutant microsomal $\Delta 12$ fatty acid desaturase gene and a full length $\Delta 15$ mutant microsomal fatty acid desaturase gene from *Brassica napus*, having an altered fatty acid profile, and the method of transformation, classified in class 800, subclass 278 for example.
- IV. Claims 31-34 are drawn to a vegetable oil with altered fatty acid ratios, extracted from the seeds of a transgenic *Brassica canola* plant transformed with a full length $\Delta 15$ mutant microsomal fatty acid desaturase gene from *Brassica napus*, classified in class 426, subclass 601 for example.

V. Claim 35 is drawn to an enzyme encoded by a $\Delta 12$ mutant microsomal fatty acid desaturase gene from *Brassica napus*, classified in class 536, subclass 23.1 for example.

Inventions 1, 2, and 3 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have been transformed with different combinations of genes that encode distinct enzymes that have discrete catalytic activities producing different products in varying degrees resulting in different phenotypes.

Inventions 1-3 and 4 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions 1-3 and 4 have different chemical composition, structure, and function. Groups 1-3 are DNA and Group 4 is oil. Group 1 is described as consisting of nucleic acids, formed in a duplex, carrying information that encodes a polypeptide while Group 4 is a carbon chain, containing both carbon single and double bonds, and functions in both membrane lipids and as a seed storage compound.

Inventions 1-3 and 5 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions 1-3 and 5 have different chemical composition, structure, and function. Groups 1-3 are DNA and Group 5 is protein. Group 1 is described as consisting of nucleic acids, formed in a

duplex, carrying information that encodes a polypeptide while Group 5 is a polypeptide, consisting of amino acids, capable of a variety of shapes, and serving as structural component of the cell or carrying out specific enzymatic or regulatory functions.

Inventions 4 and 5 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions 4 and 5 have different chemical composition, structure, and function. Group 4 is a carbon chain, containing both carbon single and double bonds, and functions structurally in membrane lipids and as a seed storage compound while Group 5 is a polypeptide, consisting of amino acids, capable of a variety of shapes, and serving as either a structural component of the cell or as an enzymatic or regulatory polypeptide.

Because the inventions are distinct for the reasons given above and have required a separate status in the art as shown by their different classifications, recognized divergent subject matter, and because the search required for one of the groups is not required for another restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Kallis whose telephone number is (703) 305-5417. The examiner can normally be reached on Monday-Friday from 8:30-5:00 PM.

If attempts to reach Examiner by telephone are unsuccessful, the Examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone number for this Group is (703) 308-4242 or (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application, or if the examiner cannot be reached as indicated above, should be directed to the legal analyst, Kim Davis, whose telephone number is (703) 308-0009.

Russell Kallis Ph.D.
April 8, 2002



**AMY J. NELSON, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600**